AKBA Stock Analysis: Buy, Sell, or Hold?
AKBA - Akebia Therapeutics, Inc.
$1.06
-0.04 (-3.64%)
▼
5d:
+7.72%
30d:
+3.92%
90d:
-22.06%
BUY
MODERATE Confidence
Analysis Updated: Jun 24, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Get Alerted When AKBA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: AKBA shows positive signals but monitor for confirmation. Market pricing in 0% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: AKBA shows positive signals but monitor for confirmation. Market pricing in 0% annual growth which appears achievable. Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: AKBA is currently trading at $1.06, which is considered extended relative to its 30-day fair value range of $0.93 to $1.05. From a valuation perspective, the stock is trading at a discount (Forward PE: -5.6) compared to its historical average (12.4). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, AKBA is in a strong downtrend. Immediate support is located at $0.82, while resistance sits at $1.14. Short-term momentum is weak, with the stock down 3.6% recently.
Market Sentiment: AKBA has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $4.20 (+296.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, AKBA is in a strong downtrend. Immediate support is located at $0.82, while resistance sits at $1.14. Short-term momentum is weak, with the stock down 3.6% recently.
Market Sentiment: AKBA has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $4.20 (+296.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$0.93 -
$1.05
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
61.9%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.6%)
- BULLISH: Trading 296.2% below Wall St target ($4.20)
- BULLISH: Market expects only 0% annual growth - appears undervalued
Trading Range Analysis
30-Day Trading Range
$0.93 -
$1.05
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$0.82
Resistance Level
$1.14
Current Trend
Strong Downtrend
Technical data as of
Jun 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.58
Wall Street Target
$4.20
(+296.2%)
Revenue Growth (YoY)
-6.6%
Profit Margin
-8.8%
PE vs Historical
-5.6 vs 12.4
CHEAP
Share & Embed Analysis
Last updated: June 24, 2026 7:16 PM ET
Data refreshes hourly during market hours. Next update: 8:16 PM
Data refreshes hourly during market hours. Next update: 8:16 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AKBA showing a specific setup today?
Insider Activity (6 Months)
1
Buys
1
Sells
0
Net
NEUTRAL
Recent Transactions
John P Butler
BUY
69270 shares
2026-03-04
Richard C Malabre
SELL
49524 shares
2026-02-02
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$194 | 59 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$105 | 60 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$125 | 57 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$665 | 60 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 59 HOLD |
Advanced AKBA Option Strategies
Professional options setups generated by AI based on today's AKBA price and gamma walls.
